
Oligonucleotide drug pipeline grows with 600+ candidates from 200+ companies advancing new therapies.
The oligonucleotide drug development pipeline is rapidly expanding, featuring over 600 candidates from more than 200 companies including Novartis, Amgen, and Alnylam. These therapies target genetic diseases, cancers, and rare disorders using advanced...


